Given that diastolic dysfunction is central to HFpEF, and diastolic function metrics are independent predictors of heart failure incidence [51], [52], our findings highlight the potential of SGLT2 inhibitor treatment to improve outcomes in individuals with MHD at risk for HFpEF. Here, SLC5A2 is linked to heart failure.